Author

David T. Rubin

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

David T. Rubin  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

David T. Rubin  et al.

HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

David T. Rubin  et al.

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

David T. Rubin  et al.

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

David T. Rubin  et al.

THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

David T. Rubin  et al.

EUROPEAN AND UNITED STATES PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE TO SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
EUROPEAN AND UNITED STATES PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE TO SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

David T. Rubin  et al.

ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

David T. Rubin  et al.

DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

David T. Rubin  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

David T. Rubin  et al.

USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE
USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE

David T. Rubin  et al.

PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

David T. Rubin  et al.

RISK FACTORS FOR DEVELOPMENT OF ACNE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH UPADACITINIB
RISK FACTORS FOR DEVELOPMENT OF ACNE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH UPADACITINIB

David T. Rubin  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

David T. Rubin  et al.

IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

David T. Rubin  et al.

EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

David T. Rubin  et al.

TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY
TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG BID VS REMAINING ON 10 MG BID IN PATIENTS WITH UC WHO WERE IN STABLE REMISSION ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

David T. Rubin  et al.

EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES
EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES

David T. Rubin  et al.

OZANIMOD-EXPOSED PATIENTS WITH ULCERATIVE COLITIS UNDERGOING TOTAL COLECTOMY EXHIBIT UNIQUE HISTOLOGIC CHANGES IN LYMPH NODES
OZANIMOD-EXPOSED PATIENTS WITH ULCERATIVE COLITIS UNDERGOING TOTAL COLECTOMY EXHIBIT UNIQUE HISTOLOGIC CHANGES IN LYMPH NODES

David T. Rubin  et al.

IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36
IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36

David T. Rubin  et al.

Item 21 - 40 / 52
1
2
3